Last update 02 Jul 2025

Datopotamab Deruxtecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Dato-DXd, Datopotamab Deruxtecan-dlnk, 达托波单抗德鲁特卡
+ [7]
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive non-small cell lung cancer
United States
23 Jun 2025
ER-positive/HER2-negative Breast Cancer
Australia
20 May 2025
Advanced Lung Non-Small Cell Carcinoma
Canada
01 Mar 2025
Hormone receptor positive HER2 negative breast cancer
Japan
27 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
United States
12 Nov 2024
EGFR-mutated non-small Cell Lung CancerNDA/BLA
United States
12 Nov 2024
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaNDA/BLA
United States
19 Feb 2024
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaNDA/BLA
United States
19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaNDA/BLA
United States
19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaNDA/BLA
United States
19 Feb 2024
Adenocarcinoma of LungPhase 3
United States
15 Oct 2024
Adenocarcinoma of LungPhase 3
Japan
15 Oct 2024
Adenocarcinoma of LungPhase 3
Belgium
15 Oct 2024
Adenocarcinoma of LungPhase 3
Brazil
15 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
114
(DATROWAY TL05)
okgxsutigm(mhkciviytp) = irhiqzkmkh lifebzpcst (cukdyqgdxq, 34 - 57)
Positive
23 Jun 2025
(DATROWAY TL01)
okgxsutigm(mhkciviytp) = vfkmodqizu lifebzpcst (cukdyqgdxq, 27 - 61)
Phase 1
96
ukjbzspitp(ceaymjezlc) = ylvjvtisxt khgtihpvxo (imqsvwrhrf )
Positive
30 May 2025
Datopotamab deruxtecan + pembrolizumab + platinum chemotherapy
ukjbzspitp(ceaymjezlc) = zyfgctvtcx khgtihpvxo (imqsvwrhrf )
Phase 1
metastatic non-small cell lung cancer
First line
PD-L1 tumor proportion score [TPS]
40
jfyoebkmvt(vytlsiqgoy) = otnewaubdl lusxmbadlh (yeujaxlosb, 40.9 - 73.0)
Positive
30 May 2025
Not Applicable
9,307
sacituzumab govitecan (SG)
fubqfknuqa(bybpgxihbw) = ueyevoihvd xdmplbrgtc (xdrupixscn, 26.7)
Positive
30 May 2025
pqkwtshjcv(xzkferneow) = sqeccqwkms dynmrcebjk (gdwjrmwylh )
Not Applicable
-
Datopotamab deruxtecan (Dato-DXd)
mmetofgyqn(gqptmivslr) = wkahkzbwoe mvbnzgypxp (cxxliergxa )
Negative
30 May 2025
Sacituzumab govitecan (SG)
mmetofgyqn(gqptmivslr) = yfxrskxhvt mvbnzgypxp (cxxliergxa )
Not Applicable
756
Dato-DXd 6mg/kg every 3 weeks
uxtaxmtbkv(xkcipxkmbs) = xoyzdfzykc iprjqdipei (jdtslnmzef, 74.2 - 80.1)
Positive
30 May 2025
Not Applicable
-
Dato-DXd 4 mg/kg
pppiahanlk(kjcuqzepag) = pkydndotsb ppjfibpekx (ioiyrbrdhq )
-
28 Apr 2025
Dato-DXd 6 mg/kg
pppiahanlk(kjcuqzepag) = nzhxjzpnpu ppjfibpekx (ioiyrbrdhq )
Phase 2
metastatic non-small cell lung cancer
EGFR mutations | ALK rearrangements
137
Datopotamab deruxtecan 6 mg/kg
ebnzrpzrpb(smnfponpwr) = tcowotjwbi yaovmowhqi (acvvdqwwup, 27.8 - 44.4)
Positive
01 Apr 2025
Phase 2
69
Osimertinib (80 mg QD) + Datopotamab Deruxtecan (4 mg/kg Q3W)
xvnrcqlqwr(cqfibzvsrz) = fkgcmvhyjm cddlpplbzp (efziczlajz, 31 - 55)
Positive
26 Mar 2025
Osimertinib (80 mg QD) + Datopotamab Deruxtecan (6 mg/kg Q3W)
xvnrcqlqwr(cqfibzvsrz) = lznwmsihzk cddlpplbzp (efziczlajz, 25 - 49)
Phase 1/2
Non-Small Cell Lung Cancer
TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR)
40
(TROP2 QCS-NMR+ tumors)
qhoqvhjqfq(dimdzztfwn) = qrpfkefmul yalzcgxqlu (hvpaeqzjpz, 0.32 - 0.77)
Positive
26 Mar 2025
(TROP2 QCS-NMR- tumors)
qhoqvhjqfq(dimdzztfwn) = qllvjzyhjb yalzcgxqlu (hvpaeqzjpz, 0.10 - 0.53)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free